Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

hims & hers health - HIMS

HIMS

Close Chg Chg %
31.49 2.35 7.46%

Closed Market

33.84

+2.35 (7.46%)

Volume: 17.62M

Last Updated:

Mar 19, 2025, 3:59 PM EDT

Trade Now

Company Overview: hims & hers health - HIMS

HIMS Key Data

Open

$31.74

 Day Range

31.02 - 34.94

52 Week Range

11.20 - 72.98

 Market Cap

$7.00B

Shares Outstanding

222.17M

 Public Float

182.04M

Beta

1.37

 Rev. Per Employee

N/A

P/E Ratio

65.18

 EPS

$0.58

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

35.63M

  

HIMS Performance

1 Week
 
 2.23%
 
1 Month
 
 -31.25%
 
3 Months
 
 29.31%
 
1 Year
 
 107.47%
 
5 Years
 
 257.93%
 

HIMS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 17
Full Ratings ➔

About hims & hers health - HIMS

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

HIMS At a Glance

Hims & Hers Health, Inc.
2269 Chestnut Street
San Francisco, California 94123
Phone 1-415-851-0195 Revenue 1.48B
Industry Medical/Nursing Services Net Income 126.04M
Sector Health Services 2024 Sales Growth 69.325%
Fiscal Year-end 12 / 2025 Employees 1,637
View SEC Filings

HIMS Valuation

P/E Current 65.182
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 45.434
Price to Sales Ratio 3.878
Price to Book Ratio 11.201
Price to Cash Flow Ratio 22.805
Enterprise Value to EBITDA 63.897
Enterprise Value to Sales 3.682
Total Debt to Enterprise Value 0.002

HIMS Efficiency

Revenue/Employee 901,963.348
Income Per Employee 76,993.28
Receivables Turnover 242.848
Total Asset Turnover 2.533

HIMS Liquidity

Current Ratio 1.788
Quick Ratio 1.497
Cash Ratio 1.356

HIMS Profitability

Gross Margin 78.296
Operating Margin 4.606
Pretax Margin 4.857
Net Margin 8.536
Return on Assets 21.619
Return on Equity 30.713
Return on Total Capital 25.824
Return on Invested Capital 30.05

HIMS Capital Structure

Total Debt to Total Equity 2.38
Total Debt to Total Capital 2.325
Total Debt to Total Assets 1.565
Long-Term Debt to Equity 1.984
Long-Term Debt to Total Capital 1.937
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Hims & Hers Health - HIMS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
271.88M 526.92M 872.00M 1.48B
Sales Growth
- +93.81% +65.49% +69.32%
Cost of Goods Sold (COGS) incl D&A
71.46M 125.67M 166.57M 320.47M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.08M 7.47M 9.52M 17.09M
Depreciation
1.98M 3.37M 6.01M 13.29M
Amortization of Intangibles
2.10M 4.10M 3.50M 3.80M
COGS Growth
- +75.86% +32.54% +92.40%
Gross Income
200.42M 401.25M 705.43M 1.16B
Gross Income Growth
- +100.20% +75.81% +63.88%
Gross Profit Margin
+73.72% +76.15% +80.90% +78.30%
2021 2022 2023 2024 5-year trend
SG&A Expense
315.46M 469.72M 738.89M 1.09B
Research & Development
- - - -
-
Other SG&A
315.46M 469.72M 738.89M 1.09B
SGA Growth
+6,483.45% +48.90% +57.30% +47.25%
Other Operating Expense
- - - -
-
Unusual Expense
(3.80M) 151.00K (2.93M) 6.10M
EBIT after Unusual Expense
(111.24M) (68.63M) (30.53M) 61.90M
Non Operating Income/Expense
445.00K 2.92M 8.96M 9.81M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(110.80M) (65.71M) (21.57M) 71.71M
Pretax Income Growth
-175.12% +40.69% +67.17% +432.44%
Pretax Margin
-40.75% -12.47% -2.47% +4.86%
Income Tax
(3.14M) (31.00K) 1.98M (54.33M)
Income Tax - Current - Domestic
252.00K 563.00K 1.99M 7.32M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(3.25M) (449.00K) (13.00K) (61.65M)
Income Tax - Deferred - Foreign
- - (142.00K) (145.00K)
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(107.66M) (65.68M) (23.55M) 126.04M
Minority Interest Expense
- - - -
-
Net Income
(107.66M) (65.68M) (23.55M) 126.04M
Net Income Growth
-167.34% +38.99% +64.15% +635.28%
Net Margin Growth
-39.60% -12.46% -2.70% +8.54%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(107.66M) (65.68M) (23.55M) 126.04M
Preferred Dividends
- - - -
-
Net Income Available to Common
(107.66M) (65.68M) (23.55M) 126.04M
EPS (Basic)
-0.5764 -0.3211 -0.1125 0.5837
EPS (Basic) Growth
+63.99% +44.29% +64.96% +618.84%
Basic Shares Outstanding
186.78M 204.52M 209.34M 215.94M
EPS (Diluted)
-0.5764 -0.3211 -0.1125 0.5322
EPS (Diluted) Growth
+63.99% +44.29% +64.96% +573.07%
Diluted Shares Outstanding
186.78M 204.52M 209.34M 236.81M
EBITDA
(110.97M) (61.00M) (23.95M) 85.09M
EBITDA Growth
-2,215.80% +45.03% +60.75% +455.35%
EBITDA Margin
-40.81% -11.58% -2.75% +5.76%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 45.813
Number of Ratings 17 Current Quarters Estimate 0.115
FY Report Date 03 / 2025 Current Year's Estimate 0.598
Last Quarter’s Earnings 0.11 Median PE on CY Estimate N/A
Year Ago Earnings 0.53 Next Fiscal Year Estimate 0.86
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 11 11 13 11
Mean Estimate 0.11 0.14 0.60 0.86
High Estimates 0.16 0.20 0.89 1.65
Low Estimate 0.06 0.08 0.21 0.29
Coefficient of Variance 27.17 29.25 29.55 39.66

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 5 6
OVERWEIGHT 0 0 1
HOLD 9 8 7
UNDERWEIGHT 1 1 1
SELL 1 1 0
MEAN Overweight Hold Overweight

Insider Actions for Hims & Hers Health - HIMS

Date Name Shares Transaction Value
Mar 14, 2025 Andrew Dudum Chief Executive Officer; Director 306,406 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 14, 2025 Irene A. Becklund PAO 22,284 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 14, 2025 Irene A. Becklund PAO 2,203 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $34.77 per share 76,598.31
Mar 7, 2025 Oluyemi Okupe Chief Financial Officer 110,319 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $5.01 per share 552,698.19
Mar 7, 2025 Christiane Pendarvis Director 11,417 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $40 per share 456,680.00
Mar 7, 2025 Oluyemi Okupe Chief Financial Officer 410,770 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Mike Chi Chief Commercial Officer 169,587 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Patrick Carroll Chief Medical Officer; Director 56,529 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Melissa Baird Chief Operating Officer 197,851 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Soleil Boughton Chief Legal Officer 98,925 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Mike Chi Chief Commercial Officer 207,642 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 26, 2025 Mike Chi Chief Commercial Officer 193,601 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $48.14 per share 9,319,952.14
Feb 21, 2025 Andrew Dudum Chief Executive Officer; Director 460,546 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $57.85 per share 26,642,586.10
Feb 21, 2025 Andrew Dudum Chief Executive Officer; Director 108,015 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.26 per share 6,292,953.90
Feb 21, 2025 Andrew Dudum Chief Executive Officer; Director 153,013 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Andrew Dudum Chief Executive Officer; Director 1,298,067 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Andrew Dudum Chief Executive Officer; Director 189,675 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $57.86 per share 10,974,595.50
Feb 21, 2025 Andrew Dudum Chief Executive Officer; Director 114,688 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $2.43 per share 278,691.84
Feb 21, 2025 Andrew Dudum Chief Executive Officer; Director 427,796 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $59.54 per share 25,470,973.84
Feb 21, 2025 Andrew Dudum Chief Executive Officer; Director 97,687 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $59.69 per share 5,830,937.03

Hims & Hers Health in the News